Benjamin Graham fit · Defensive deep-value investing
Is Cytek Biosciences, Inc. Common Stock (CTKB) a Benjamin Graham Stock?
Meets only 3/7 Graham criteria — likely overpriced or unstable.
20/100
FNot a fit
3/7 criteria passed
Benjamin Graham's Criteria, Applied to CTKB
P/E ≤ 15
key—
P/B ≤ 1.5
key0.0x
Current ratio ≥ 2
5.2x
Debt / Equity ≤ 1
0.0x
5y profitable
keyNo
Earnings yield ≥ 7%
-1.8%
Revenue growing
-23.7%
How CTKB Scores on Other Strategies
Live Financial Snapshot
Market cap
$547.56M
P/E (TTM)
-
ROIC (TTM)
-11.42%
Gross margin
51.7%
Other Benjamin Graham fit reports
Frequently Asked Questions
What is CTKB's Benjamin Graham fit score?
CTKB scores 20/100 on our Benjamin Graham fit engine — grade F. Meets only 3/7 Graham criteria — likely overpriced or unstable.
Does Benjamin Graham actually own CTKB?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends CTKB.
How often is this score updated?
CTKB's Benjamin Graham fit score is recomputed daily from the latest TTM financials.
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Benjamin Graham personally owns or recommends CTKB.